BioMotiv, the for-profit accelerator of The Harrington Project, is the developer and lead funder of OptiKira. BioMotiv aims to advance a portfolio of discoveries into new medicines through an innovative, mission-driven model that efficiently aligns capital and collaborations for the benefit of inventors and investors, and ultimately physicians and patients.
Arix Bioscience, a global healthcare and life science company supporting medical innovation, has committed $25 million to BioMotiv and has announced that it will provide development capital to Optikira.
Charles River Laboratories and BioMotiv have formed a partnership that will leverage the strengths of both organizations to advance discoveries sourced from academic research and non-governmental organizations into novel medicines. Charles River Laboratories is the preferred partner for preclinical drug development of OptiKira.
Becoming a Partner
We are open to partnering with other organizations. Please reach out to us via the form below if you or your company are interested in partnering with OptiKira.